All Categories
CHHiP Trial Evaluates a Multimodal AI Biomarker in Localized...
Anna Wilkins describes her validation of the Artera MMAI biomarker, drawing on over 2,000 biopsies from the 3,200-patient CHH [...]
ASCO to shine light on multimodal AI models: Plus,...
Dr. Lu will highlight recent work using specimens from the NRG B-20 trial, in which investigators applied multimodal AI appro [...]
Artera Secures CE Marking for Its AI Prostate and...
Dual regulatory milestones establish Artera as a global AI leader in precision oncology SAN FRANCISCO, April 21, 2026— Artera [...]
Artera Product Webinar April 2026
The ArteraAI Prostate Test is transforming the risk stratification landscape for treating prostate cancer. For lower-risk pat [...]
Balancing survival and quality of life: The evolving role...
Traditional oncology metrics have long measured success in survival curves and hazard ratios, not in days spent comfortably w [...]
Cost-effectiveness of an artificial intelligence predictive model for guiding...
The ArteraAI Prostate Test (ArteraAI Inc.) is the first predictive biomarker for benefit of adding short-term androgen depriv [...]
Validation of Multimodal and Image-Only Artificial Intelligence Digital Pathology–Based...
Accurate risk stratification is essential to personalizing treatment decision-making in prostate cancer, enabling escalation [...]
Reimagining Cancer Care: The Role of Artificial Intelligence in...
Eliezer Van Allen discusses his keynote address on artificial intelligence in cancer care, describing the transition from sta [...]